Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Biotechnology

Healthcare
$28.46 +3.66%

+$0.61 today

Market cap
$4.61B
Beta
2.15
P/E (TTM)
-54.5
EPS (TTM)
-$0.32
52W Low $9.96High $20.76

Volume 2.21M

Average 1.94M

ADPT Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Adaptive Biotechnologies CorporationNASDAQ: ADPT

Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026

Cost of revenue growth accelerates

Q2 FY2026 cost of revenue of $20.59M rose 14.4% year over year, ahead of the +8.6% change in trailing-twelve-month cost of revenue. Sequentially, it rose 10.0% from the prior quarter. Over 3 fiscal years it compounded at +7.2% a year.

Context

  • Cost of revenue amounted to 25.8% of revenue in FY2025, down 14.5 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +14.4% holds above the trailing-twelve-month pace of +8.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$20.59M+10.0% QoQ
Last fiscal yearDec 2025
$71.36M-1.0% YoY
LTMJun 2026
$75.68M+8.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.4%——
1 year-1.0%——
3-year CAGR+7.2%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
71.36M USD
Year-over-year change
-1.0%
4-year CAGR
+9.7%

Cost of Revenue vs competitors

How ADPT compares with its peers on the latest reported figures

  • ADPT's LTM Jun 2026 cost of revenue of $75.68M is the 6th highest of the 10 companies compared; the peer median is $105.52M.
  • Its year-over-year change of +8.6% is the 6th highest of 7, against a peer median of +52.6%.
  • Cost of revenue amounts to 24.6% of revenue for ADPT, versus a peer median of 43.5%.
ADPT Competitors Peer median
Cost of Revenue for ADPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$678.51M +1556.2%+217.9%99.5%
LEGNLegend Biotech CorporationLTM Sep 2026$584.36M +63.0%+84.1%43.0%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$244.96M +232.7%+29.8%108.7%
ZLABZai Lab LimitedLTM Jun 2026$195.71M +21.7%+37.2%43.5%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$105.52M +42.1%+36.4%17.7%
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026$75.68M +8.6%+7.2%24.6%
SRRKScholar Rock Holding CorporationLTM Sep 2026$47.52M -52.5%+19.2%8336.0%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$21K ———
IRONDisc Medicine, Inc.LTM Sep 2026$0 ———
BEAMBeam Therapeutics Inc.LTM Jun 2026$0 —-58.5%0.0%
Peer median (excluding ADPT) $105.52M+52.6%+36.4%43.5%

Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue154.34M185.31M170.28M178.96M276.98M
Cost of Revenue49.3M57.91M75.55M72.08M71.36M
Gross Profit105.04M127.4M94.72M106.88M205.62M
Gross Margin68.1%68.7%55.6%59.7%74.2%
Research & Development142.34M141.76M122.12M102.95M93.77M
Selling, General & Admin169.97M184.13M172.51M157.57M167.27M
Operating Expenses314.01M327.59M321.76M269.43M262.74M
Depreciation & Amortization13.95M20.92M22.23M19.26M17.83M
EBITDA(193.35M)(175.21M)(189.27M)(128.76M)(29.85M)
EBITDA Margin-125.3%-94.6%-111.2%-71.9%-10.8%
Operating Income(208.97M)(200.19M)(227.04M)(162.55M)(57.12M)
Operating Margin-135.4%-108.0%-133.3%-90.8%-20.6%
Interest Income1.67M4.06M15.53M14.53M9.44M
Interest Expense04.24M13.8M11.58M11.78M
Other Income / Expenses1.67M(182K)1.73M2.95M(2.33M)
Income Before Tax(207.3M)(200.37M)(225.3M)(159.6M)(59.46M)
Pre-Tax Margin-134.3%-108.1%-132.3%-89.2%-21.5%
Income Tax Expense00000
Net Income(207.28M)(200.19M)(225.25M)(159.49M)(59.5M)
Net Margin-134.3%-108.0%-132.3%-89.1%-21.5%
EPS (Basic)(1.46)(1.00)(1.56)(1.08)(0.39)
EPS (Diluted)(1.46)(1.00)(1.56)(1.08)(0.39)
Weighted Avg Shares140.35M142.52M144.38M147.1M151.72M
Weighted Avg Shares (Diluted)140.35M142.52M144.38M147.1M151.72M

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Intrinsic Alpha fair value

Locked

Current Price

$28.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.